Lista de obras - Michele Del Vecchio - Dominio Público Uruguay

A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck

scientific article published on 01 July 1994

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

artículo científico

Allovectin-7 therapy in metastatic melanoma

scientific article published on 01 June 2008

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

artículo científico publicado en 2018

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

artículo científico publicado en 2016

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

artículo científico publicado en 2010

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

artículo científico publicado en 2017

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

artículo científico publicado en 2004

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

artículo científico publicado en 2014

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.

artículo científico publicado en 2016

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

artículo científico publicado en 2016

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

artículo científico publicado en 1997

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio

artículo científico publicado en 2016

Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

article

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

artículo científico publicado en 2009

Impressive objective response in a patient with extensive metastatic melanoma including the brain

artículo científico publicado en 2007

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

artículo científico publicado en 2013

Interleukin-12: biological properties and clinical application

artículo científico publicado en 2007

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience

artículo científico publicado en 2019

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

artículo científico publicado en 2014

Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.

artículo científico publicado en 2003

Metastatic melanoma: chemotherapy

artículo científico publicado en 2002

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

artículo científico publicado en 2006

Neuroendocrine tumors (NETs)

scientific article published on 01 September 2009

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

artículo científico publicado en 2017

Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

artículo científico publicado en 2004

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

artículo científico publicado en 2016

Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

artículo científico publicado en 2016

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

artículo científico publicado en 2014

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

artículo científico publicado en 2013

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma

article

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

artículo científico publicado en 2014

Treatment of cancer-related anemia with epoetin alfa: a review.

artículo científico publicado en 2004

Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma

scientific article published on 01 February 2004

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

artículo científico publicado en 2015

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

artículo científico publicado en 2014

[AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab].

artículo científico publicado en 2016

Lista de obras de Michele Del Vecchio

A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Allovectin-7 therapy in metastatic melanoma

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio

Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

Impressive objective response in a patient with extensive metastatic melanoma including the brain

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

Interleukin-12: biological properties and clinical application

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.

Metastatic melanoma: chemotherapy

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

Neuroendocrine tumors (NETs)

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Treatment of cancer-related anemia with epoetin alfa: a review.

Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

[AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab].